Cancer advocacy group lashes out at NICE's Lynparza No; Actavis closes on Auden Mckenzie deal;

@FiercePharma: ICYMI: Adding Opdivo to Yervoy ups melanoma treatment efficacy--but it ups rate of serious side effects, too. Report | Follow @FiercePharma

@CarlyHFierce: UPDATED w/Genentech comment: Roche's Gazyva doubles remission time for non-Hodgkin lymphoma patients. Story | Follow @CarlyHFierce

> No sooner had England's cost-effectiveness watchdogs issued a preliminary rejection to AstraZeneca's ($AZN) ovarian cancer drug Lynparza than Cancer Research UK stepped up to criticize it. Report

> Actavis ($ACT) wrapped up its £306 million buyout of niche U.K. drugmaker Auden Mckenzie. Release

> The health insurer Anthem ($WLP) says its new method for reimbursing cancer treatment has helped push doctors to use recommended regimens. Report

> India's retail drug-sellers plan a nationwide campaign against online medication sales. Report

> Foster Farms says it plans to mostly eliminate antibiotics used to treat human illnesses in its poultry. Report

> Teva Pharmaceutical ($TEVA) rolled out its generic version of Actonel, the osteoporosis med, and has 180-day exclusivity on the copy. Report

Medical Device News

@FierceMedDev: ICYMI: DOJ slaps Olympus with a subpoena over dirty duodenoscopes. Article | Follow @FierceMedDev

@VarunSaxena2: FMD exclusive (got insider tip): Zimmer to cut some staff as it barrels toward merger with Biomet. Story | Follow @VarunSaxena2

@EmilyWFierce: ICYMI from FiercePharma: Otsuka faces the music for generic Abilify, loses battle with FDA. Article | Follow @EmilyWFierce

> Molecular Dx: Invitae drops prices as NIH starts 1,000-patient, molecular abnormalities cancer study. More

> Startup Arsenal Medical and its spinoff raise $26.5M to develop novel foam, nanofiber and bioresorbable products. Article

Biotech News

@FierceBiotech: ASCO 15: The top 10 setbacks, advances and head scratchers. Editor's corner | Follow @FierceBiotech

@JohnCFierce: $IMGN shares up 14% on positive early data for ovarian cancer ADC. Release | Follow @JohnCFierce

> Bristol-Myers barrels toward approval with a blockbuster cancer combo. More

> Juno amps up its CAR-T tech in drive toward a pivotal test. Report

> Bristol-Myers fires off a lawsuit to sideline R&D defector headed to rival AstraZeneca. Story

> Alzheimer's biotech eyes $300M in a scaled-up IPO. Article

Animal Health News

> Tech makers market health wearables to dog owners. Item

> Groundbreaking held for the new $1.2B NABF animal health facility in Kansas. More

> Bayer CEO Dekkers looking 'with interest' at animal-health additions. Report

> K-State researchers build avian-flu protection into existing poultry vaccine. Article

> Novozymes enters booming market for poultry probiotics. Story

Biotech IT News

> CRISPR Therapeutics starts search for a bioinformatics chief. More

> Bioinformatics leads UCSD team to ovarian cancer biomarkers. Story

> AstraZeneca's Definiens rolls out biomarker data service. Item

> Artificial intelligence tops Google VC's list of high-potential life sci techs. Article

> UT Southwestern snags $5.6M grant to boost bioinformatics operation. Report

Pharma Marketing News

> Stars of cancer meeting set to crack top 10 cancer sales by 2020. Article

> Valeant plots big DTC push for Xifaxan while rival Actavis drug waits on DEA. Report

> Novartis rolls out 'life hacks' for MS patients with new Live Like You campaign. Article

> ASCO must-reads: Pfizer's Ibrance; BMS, Novartis melanoma meds; J&J's Imbruvica and more. More

> Abbott takes Pedialyte on the festival circuit as grown-up hangover remedy. Story

And Finally... The high-protein versus low-fat debate plays out in Dean Ornish scuffle in Scientific American. Report

Suggested Articles

In previously untreated nonsquamous NSCLC, a Tyvyt-chemo combo beat chemo alone at stalling the time to tumor progression or death.

It’s been a big year for Bristol's Opdivo-Yervoy combo in lung cancer, but with new mesothelioma data in hand, the duo isn’t done making headlines.

A third spinal muscular atrophy treatment option is set to debut with the FDA’s approval for Roche’s Evrysdi, formerly known as risdiplam.